Parthenolide and EpoY attenuated increased microtubule detyrosination and membrane stiffness, and restored sodium current in PKP2-deficient mouse and human cardiomyocytes.
Do compounds that decrease microtubule detyrosination improve cardiac mechanics and sodium channel function in models of arrhythmogenic cardiomyopathy?
Decreasing microtubule detyrosination represents a novel therapeutic target to improve contractile and electrical function in arrhythmogenic cardiomyopathy.
BACKGROUND: Alterations in microtubule dynamics have been shown to affect cardiomyocyte membrane stiffness and modulate ion channels, including the cardiac sodium channel. While conditions, such as heart failure and Duchenne muscular dystrophy, are associated with increased detyrosination of microtubules and reduced sodium current, a potential role for microtubule detyrosination in arrhythmogenic cardiomyopathy has not been explored. We here investigated the impact of microtubule detyrosination on membrane stiffness, cardiac sodium channel distribution, and function in mouse and human models of arrhythmogenic cardiomyopathy. METHODS: Isolated ventricular cardiomyocytes from mice with cardiomyocyte-specific, tamoxifen-activated knockout of PKP2 (plakophilin-2), as well as PKP2 -c.2013delC, and isogenic control human-induced pluripotent stem cell–derived-cardiomyocytes were incubated for 2 to 4 hours with compounds known to decrease microtubule detyrosination (parthenolide, 10 µmol/L; EpoY, 20 µmol/L) or vehicle (dimethyl sulfoxide). Immunocytochemistry, mechano-scanning ion conductance microscopy, patch-clamp analysis, and stochastic optical reconstruction microscopy were performed. RESULTS: Cardiomyocyte-specific, tamoxifen-activated knockout of PKP2 cardiomyocytes displayed increased microtubule detyrosination and membrane stiffness, which were both attenuated by parthenolide treatment. Parthenolide significantly increased whole-cell sodium current density in cardiomyocyte-specific, tamoxifen-activated knockout of PKP2 mouse cardiomyocytes, with macropatch measurements demonstrating that this increase occurred both at the intercalated disc and lateral membrane. Stochastic optical reconstruction microscopy analysis revealed that parthenolide increased cardiac sodium channel cluster density at the intercalated disc of cardiomyocyte-specific, tamoxifen-activated knockout of PKP2 mouse cardiomyocytes. In contrast, parthenolide had no effect on sodium current, cardiac sodium channel cluster size, or density in cardiomyocytes from control mice. PKP2 -c.2013delC human-induced pluripotent stem cell–derived-cardiomyocytes displayed increased microtubule detyrosination and reduced sodium current compared with isogenic control human-induced pluripotent stem cell–derived-cardiomyocytes, which were both prevented by parthenolide and EpoY. CONCLUSIONS: Increased microtubule detyrosination secondary to loss of PKP2 impacts cardiomyocyte (dys)function beyond the desmosome, contributing to both electrical and mechanical alterations in the setting of arrhythmogenic cardiomyopathy. Our findings identify microtubule detyrosination as a novel therapeutic target in pathophysiological conditions, such as arrhythmogenic cardiomyopathy, aimed at improving both contractile and electrical function.
Nasilli et al. (Mon,) conducted a other in Arrhythmogenic cardiomyopathy. Compounds decreasing microtubule detyrosination (parthenolide, EpoY) vs. Vehicle (dimethyl sulfoxide) was evaluated on Membrane stiffness, cardiac sodium channel distribution, and function. Parthenolide and EpoY attenuated increased microtubule detyrosination and membrane stiffness, and restored sodium current in PKP2-deficient mouse and human cardiomyocytes.